Recent Finacing
Recent Raise
AN2 Therapeutics is a Menlo Park clinical-stage biopharma developing epetraborole, an oral once-daily investigational therapy for chronic non-tuberculous mycobacterial lung disease, and partners with Brii Biosciences in China.
